Cryoviva

What Cryoviva does

Cryoviva Biotech Private Limited is an Indian umbilical cord blood and cord tissue stem cell bank founded in 2006 and headquartered in Gurgaon, Haryana. Operating as the healthcare vertical of the diversified RJ Corp conglomerate (parent of Varun Beverages and Devyani International), Cryoviva runs a 28,000 square-foot state-of-the-art processing and storage facility and serves more than 300,000 parent customers across India and international markets including Singapore, Thailand, Nepal, Vietnam, the UAE, Oman, and Bahrain.

The company's core offering is end-to-end stem cell banking — collection via proprietary closed-bag transfer kits at partner hospitals, processing using USFDA-cleared Sepax automated technology (FACT and AABB accredited, claimed to deliver up to 52% higher cell yield than open processing), and long-term cryogenic storage at -196°C. Beyond the Sepax platform, Cryoviva has developed a proprietary non-enzymatic Explant Technique for mesenchymal stem cell (MSC) processing that it positions as trade-secret-protected IP. The product portfolio spans four tiers (Super Saver, Saver, Blessing Plus, and premium Cryo Supra with ready-to-use MSCs), additional services including CFU Assay, HLA High Resolution typing, New Born Screening, Astro DNA testing, and Lifetime Storage, and two banking models: Family Banking (private dedicated storage) and Social Banking (a shared pool model designed to improve HLA matching probability).

Cryoviva generates revenue primarily through subscription contracts that bundle processing fees with multi-year (up to 21-year) storage fees, supplemented by one-time fees for ancillary services. The go-to-market is sales-led and direct-to-consumer, leveraging a pan-India network of 200+ cities and towns via OB-GYN referral partnerships, free home presentations, and customer referral programs. Distribution internationally is executed through wholly-owned subsidiaries (Singapore, Thailand, Nepal, Vietnam) and channel partners (UAE, Oman, Bahrain). The company holds a full stack of accreditations — AABB, CAP, ISO 9001:2015, NABL, DCGI, WHO GLP, and cGMP/SGS — positioning it as one of the most credentialed stem cell banks operating from India.

Name

Cryoviva

Legal name

Cryoviva Biotech Private Limited

Website

https://cryoviva.in

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Cryoviva is an Indian umbilical cord blood and cord tissue stem cell bank serving expectant parents globally, with 300,000+ customers and operations across India, Southeast Asia, the Gulf, and East Africa.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Cord blood banking
• Stem cell storage
• Umbilical cord preservation
• Family stem cell banking
• Social stem cell banking

Headquarters

HQ city

Gurugram

HQ country

India

HQ region

Asia

Offices8 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Stem Cell Banking Services: Cryoviva generates revenue through cord blood and cord tissue stem cell banking services. The company offers multiple product tiers (Super Saver, Saver, Blessing Plus, Cryo Supra) with both family banking and social banking options. Revenue comes from processing fees and storage fees over contract periods up to 21 years.
2. Additional Services: Additional services including CFU Assay, HLA High Resolution typing, New Born Screening, Astro DNA testing, and Lifetime Storage options.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Cryoviva provides umbilical cord blood and cord tissue stem cell banking services for expectant parents. The company collects cord blood at the time of delivery, processes it using USFDA-cleared Sepax automated technology at its 28,000 sq ft facility in Gurugram, and cryogenically stores samples at -196°C for contract periods up to 21 years. Services span Family Banking (private storage) and Social Banking (shared pool model) options, supported by HLA typing and newborn screening add-ons.

Product overview

Cryoviva offers a comprehensive umbilical cord blood and cord tissue stem cell banking service through multiple product tiers. The core product portfolio includes Saver, Blessing Plus, Super Saver, and Cryo Supra - ranging from basic cord blood preservation to premium offerings with advanced MSC processing. Additional services encompass C.F.U. Assay, H.L.A. High Resolution, New Born Screening, Astro DNA, and Life Time Storage. The company provides two banking models: Family Banking (exclusive private storage) and Social Banking (shared pool with matching access). Key services include automated Sepax processing technology, proprietary Explant MSC processing, and professional collection and long-term storage facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Super Saver: Product for preserving baby's cord blood stem cells at birth
• Saver
• Blessing Plus
• Cryo Supra

Products and services

• Family Banking
• Social Banking
• Collection Services
• Sepax Processing Service
• Explant MSC Processing Service
• Storage Services
• C.F.U Assay
• H.L.A High Resolution Typing
• New Born Screening
• Astro DNA
• Life Time Storage

Quantifiable outcome

• Sepax can harvest up to 52% more cell count compared to open processing method, enabling treatment of patients weighing up to 60kg vs 40kg from same cord blood unit
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Smart Cells International: UK-headquartered private stem cell bank with international expansion in India and Middle East. Directly comparable on the Sepax processing platform, family banking pricing tiers, and the international-presence model Cryoviva aspires to.
• CBR (Cord Blood Registry) / CooperSurgical: Largest US private cord blood bank, now part of CooperSurgical. Sets global best-in-class benchmarks on Sepax technology, AABB standards, and direct-to-consumer marketing that Cryoviva benchmarks itself against.
• ReeLabs: Indian stem cell banking and processing company offering umbilical cord, menstrual blood, and adipose-derived stem cell banking. Competes with Cryoviva on price, technology positioning, and the same expectant-parent customer segment.
• StemCyte India Therapeutics: Operates both private and public cord blood banks in India with a focus on therapeutic-grade stem cell products. Direct competitor in social/community banking and in the advanced MSC product tier.
• LifeCell International: India's largest private stem cell and cord blood banking company; competes head-to-head with Cryoviva in family banking, has community stem cell bank (LifeCell Community), and offers similar service portfolio including HLA typing and CFU assays.
• Cordlife Group Limited: Singapore-listed (and India-domiciled Cordlife Sciences India) cord blood banking operator with multi-country presence across Asia. Direct competitor on processing technology, AABB accreditation, and pricing tiers in the Indian and Southeast Asian markets.
• ViaCord (Revvity): US-based family cord blood and cord tissue bank, now part of Revvity. Direct peer on premium MSC products, AABB accreditation, and USFDA-cleared processing. Comparable in product tiering and lifetime storage positioning.
• Cryo-Save / Esperite: European-headquartered family stem cell bank with historical presence in India. Direct peer in international expansion, family banking model, and biobanking regulatory standards.

Others

• Thermo Fisher Scientific (Cell Therapy Services): Provides cryopreservation media, controlled-rate freezers, and cell therapy manufacturing services used by cord blood banks including Cryoviva. Acts as an enabling technology and supply-chain peer rather than a direct competitor.

Regional players

• Cells4Life: UK-focused private cord blood and tissue bank with a regional concentration that limits direct India overlap, but uses the same Sepax platform and AABB-aligned processes; serves as a reference peer for technology and pricing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/Cryoviva_India
• Facebookfacebook.com/CryovivaIndia

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cryoviva